DOCSLIB.ORG

Peripheral Tolerance Can Be Modified by Altering KLF2-Regulated Treg Migration

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Peripheral Tolerance Can Be Modified by Altering KLF2-Regulated Treg Migration Peripheral tolerance can be modified by altering KLF2-regulated Treg migration Sudheer K. Pabbisettya, Whitney Rabacala, Emmanuel J. Volanakisb, Vrajesh V. Parekha, Danyvid Olivares-Villagómeza, Delphine Cendrona, Kelli L. Boyda, Luc Van Kaera, and Eric Sebzdaa,1 aDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232; and bDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232 Edited by Rafi Ahmed, Emory University, Atlanta, GA, and approved June 20, 2016 (received for review April 12, 2016) Tregs are essential for maintaining peripheral tolerance, and thus diseases. Together, these results suggest that KLF2 is a therapeutic targeting these cells may aid in the treatment of autoimmunity and target for fine-tuning self-tolerance in a temporal fashion by altering cancer by enhancing or reducing suppressive functions, respectively. Treg migration patterns. Before these cells can be harnessed for therapeutic purposes, it is necessary to understand how they maintain tolerance under phys- Results iologically relevant conditions. We now report that transcription KLF2 Acts as a Rheostat to Control Expression of Treg Homing Receptors. factor Kruppel-like factor 2 (KLF2) controls naive Treg migration In contrast to conventional T cells that recirculate between SLOs patterns via regulation of homeostatic and inflammatory homing via blood and lymph, Tregs exhibit an expanded migratory pattern receptors, and that in its absence KLF2-deficient Tregs are unable that includes tertiary tissues (14). A previous report demonstrated to migrate efficiently to secondary lymphoid organs (SLOs). Diminished that KLF2 maintains naive T cells in a homeostatic migration Treg trafficking to SLOs is sufficient to initiate autoimmunity, pattern and, much like activated lymphocytes that quickly degrade indicating that SLOs are a primary site for maintaining peripheral this transcription factor, Klf2 excision causes quiescent T cells to tolerance under homeostatic conditions. Disease severity correlates vacate SLOs and enter peripheral tissues (15). Interestingly, Tregs + − with impaired Treg recruitment to SLOs and, conversely, promotion express half the amount of KLF2 as conventional CD4 CD25 of Tregs into these tissues can ameliorate autoimmunity. Moreover, T cells (Fig. 1A), possibly explaining the hybrid migration pattern stabilizing KLF2 expression within the Treg compartment enhances exhibited by this regulatory lineage. In addition, we identified a set peripheral tolerance by diverting these suppressive cells from tertiary of inhibitory compounds that elevated KLF2 levels within the Treg tissues into SLOs. Taken together, these results demonstrate that compartment (16), raising the possibility that we could manipulate peripheral tolerance is enhanced or diminished through modulation Treg migration pharmaceutically by targeting KLF2. To test this of Treg trafficking to SLOs, a process that can be controlled by exciting prospect, we initially identified an array of homing recep- adjusting KLF2 protein levels. + tors that were differentially expressed in Tregs relative to CD4 T cells both at the mRNA (Fig. 1B) and protein level (Fig. 1C). KLF2 | regulatory T cell | Treg migration | autoimmunity | Focusing on these receptors, we next confirmed that KLF2- peripheral tolerance fl/fl deficient Tregs harvested from Foxp3-cre; Klf2 mice displayed an altered transcription pattern that was consistent with KLF2- regs are necessary to maintain peripheral tolerance, and in their promoting (e.g., CCR7 and S1P1) or -suppressing (e.g., CCR4, Tabsence autoimmunity is 100% penetrant in both humans and CCR8, and CCR9) homeostatic and inflammatory receptors, re- mice (1, 2). This discovery highlights a key feature of self-tolerance, spectively (Fig. 1D). Where available, commercial antibodies namely that autoreactive lymphocytes are present in all healthy were used to verify RT-PCR results; alternatively, ex vivo migration individuals and that these cells must be continuously suppressed by Tregs to avoid disease. Conversely, reports indicate that tumor cells Significance co-opt the Treg compartment to suppress tumor surveillance (3–10), thereby allowing cancer progression toward malignancy. Modifying Treg activity offers a potential means of treating these Tregs are necessary to prevent autoimmunity; however, these diseases, either by promoting (autoimmunity) or diminishing (tumor same cells suppress tumor-specific immune responses and con- surveillance) self-tolerance. As such, targeting Treg migration is an tribute to malignancy. Before Treg-based therapies are devised to appealing technique that could increase or decrease self-tolerance treat these diseases, it is important to understand how Tregs in a spatially and temporally limited manner. Studies of in vivo Treg function under physiological conditions. We now report that Tregs activity are further complicated by the finding that naive Tregs carry out their immune-suppressive functions in secondary lym- traffic freely between secondary lymphoid organs (SLOs) and ter- phoid organs (e.g. spleen, lymph nodes) and factors that impair or tiary tissues (11–13), raising the question as to where Treg-mediated enhanceTreghomingtothesesitesdiminishorincreaseself- tolerance is carried out. We now report that intermediate levels of tolerance, respectively. Importantly, Treg migration patterns are regulated by Kruppel-like factor 2 (KLF2), and increasing expression Kruppel-like factor 2 (KLF2) are responsible for a hybrid expres- of this transcription factor within the Treg compartment promotes sion of homeostatic and inflammatory homing receptors displayed self-tolerance. The present study demonstrates that Treg traffick- on the surface of Tregs that underpin regulatory circulation pat- ing to lymphoid tissues underpins peripheral tolerance, which can terns. Excision of Klf2 within the Treg compartment shifts the be modified by targeting KLF2 with therapeutic drugs. balance of Treg migration away from SLOs and toward peripheral tissues, whereas increasing KLF2 expression encourages Treg re- Author contributions: S.K.P. and E.S. designed research; S.K.P., W.R., E.J.V., V.V.P., D.O.-V., D.C., cruitment into SLOs. With regard to peripheral tolerance, hindering and K.L.B. performed research; E.J.V. and L.V.K. contributed new reagents/analytic tools; S.K.P., Treg entry into SLOs is by itself sufficient to induce autoimmunity, W.R., L.V.K., and E.S. analyzed data; and S.K.P. and E.S. wrote the paper. the severity of which correlates with defective Treg trafficking into The authors declare no conflict of interest. these tissues. Conversely, enhancing Treg migration toward SLOs, This article is a PNAS Direct Submission. either by augmenting KLF2 levels or increasing the expression of 1To whom correspondence should be addressed. Email: [email protected]. SLO-centric homing receptors governed by this transcription factor, This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. reestablished peripheral tolerance and ameliorated T-cell–mediated 1073/pnas.1605849113/-/DCSupplemental. E4662–E4670 | PNAS | Published online July 26, 2016 www.pnas.org/cgi/doi/10.1073/pnas.1605849113 Downloaded by guest on September 24, 2021 PNAS PLUS A KLF2 B 0.003 tubulin 1.0 1.0 <0.0001 0.002 + + 0.75 0.75 KLF2 CD4 T cell KLF2+ Treg 0.5 0.5 0.25 0.25 (RT-PCR) 0.04 0.01 0.140.14 0.030.03 (relative to tubulin) KLF2 protein levels 0 0 Relative mRNA levels Relative mRNA Treg Treg 1 Klf2 S1P naive T cell CCR4 CCR6 CCR7 CCR8 CCR9 activated T cell memory T cell Treg+ Tregrapamycin + LY294002 conventional T cellTreg + simvastatin D 0.008 0.0005 + C 100 100 0.02 KLF2 Treg 80 80 KLF2-/- Treg 60 60 0.008 40 40 (RT-PCR) 0.001 0.04 <0.0001 20 20 0 0 Relative mRNA levels Relative mRNA 0102 10 3 10 4 10 5 0102 10 3 10 4 10 5 1 CCR4 CCR6 CCR7 Klf2 CCR4 CCR6 CCR7 CCR8 CCR9 S1P 100 100 100 80 80 80 F 100 100 60 60 60 80 80 Relative cell number 40 40 40 60 60 20 20 20 40 40 0 0 0 0102 10 3 10 4 10 5 0102 10 3 10 4 10 5 0102 10 3 10 4 10 5 20 20 CCR8 CD44 CD62L 0 0 2 3 4 5 0102 10 3 10 4 10 5 010 10 10 10 P=0.001 CCR4 CCR8 100 100 100 E 50 50 100 100 80 80 80 40 80 80 60 60 60 30 Relative cell number 60 60 40 40 40 25 20 40 40 20 20 20 10 to CCL25 0 20 20 0 0 2 3 4 5 0 2 3 4 5 010 10 10 10 2 3 4 5 010 10 10 10 010 10 10 10 0 WT cKO % Treg migration % Treg fl/fl Foxp3-cre; 0 0 Klf2 0102 10 3 10 4 10 5 0102 10 3 10 4 10 5 CCR4 CCR6 CCR7 Klf2fl/fl 100 100 100 CD44 CD62L 15 P=0.01 80 15 80 80 KLF2+ Treg Relative cell nubmer 60 60 60 10 KLF2+ Treg + simvastatin 40 40 40 7.5 -/- 20 20 20 5 KLF2 Treg + simvastatin to S1P 0 0 0 2 3 4 5 010 10 10 10 2 3 4 5 2 3 4 5 010 10 10 10 010 10 10 10 INFLAMMATION 0 P=0.002 WT cKO IMMUNOLOGY AND % Treg migration % Treg 0 P<0.0001 CCR8 CD44 CD62L Klf2fl/fl Foxp3-cre; 50 1000 1000 fl/fl Klf2 800 600 25 500 G Klf2fl/fl mice Foxp3-cre; Klf2fl/fl mice 400 to S1P 200 to CCL19 migration % migration 0.03 0 25 0 untreated simvastatin 25 media 0 20 0.72 20 simvastatin 0.21 0.5 0.62 15 15 0.12 untreated untreated 0.02 10 10 + simvastatinP<0.0001 + simvastatin 0.7 50 50 Treg numbers Treg 5 numbers Treg 5 40 0 0 25 30 4 ) 4 ) 5 ) 4 ) 4 ) 5 ) 20 0 3 /ml) 0 0 3 /ml) 10 to CCL25 % migration 0 0 control KO Ax LN (x1 Ms LN (x10 Spleen (x10 Ms LN (x1Ax LN (x1Spleen (x10 Blood (x10 Blood (x10 untreated + simvastatin Fig.
Load more

Recommended publications
  • CCR8 Expression Defines Tissue-Resident Memory T Cells in Human Skin Michelle L
    CCR8 Expression Defines Tissue-Resident Memory T Cells in Human Skin Michelle L. McCully, Kristin Ladell, Robert Andrews, Rhiannon E. Jones, Kelly L. Miners, Laureline Roger, This information is current as Duncan M. Baird, Mark J. Cameron, Zita M. Jessop, Iain S. of September 24, 2021. Whitaker, Eleri L. Davies, David A. Price and Bernhard Moser J Immunol published online 2 February 2018 http://www.jimmunol.org/content/early/2018/02/02/jimmun Downloaded from ol.1701377 Supplementary http://www.jimmunol.org/content/suppl/2018/02/02/jimmunol.170137 Material 7.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 24, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Author Choice Freely available online through The Journal of Immunology Author Choice option Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2018 The Authors All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published February 2, 2018, doi:10.4049/jimmunol.1701377 The Journal of Immunology CCR8 Expression Defines Tissue-Resident Memory T Cells in Human Skin Michelle L.
    [Show full text]
  • G Protein-Coupled Receptors As Therapeutic Targets for Multiple Sclerosis
    npg GPCRs as therapeutic targets for MS Cell Research (2012) 22:1108-1128. 1108 © 2012 IBCB, SIBS, CAS All rights reserved 1001-0602/12 $ 32.00 npg REVIEW www.nature.com/cr G protein-coupled receptors as therapeutic targets for multiple sclerosis Changsheng Du1, Xin Xie1, 2 1Laboratory of Receptor-Based BioMedicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sci- ences and Technology, Tongji University, Shanghai 200092, China; 2State Key Laboratory of Drug Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shou Jing Road, Pudong New District, Shanghai 201203, China G protein-coupled receptors (GPCRs) mediate most of our physiological responses to hormones, neurotransmit- ters and environmental stimulants. They are considered as the most successful therapeutic targets for a broad spec- trum of diseases. Multiple sclerosis (MS) is an inflammatory disease that is characterized by immune-mediated de- myelination and degeneration of the central nervous system (CNS). It is the leading cause of non-traumatic disability in young adults. Great progress has been made over the past few decades in understanding the pathogenesis of MS. Numerous data from animal and clinical studies indicate that many GPCRs are critically involved in various aspects of MS pathogenesis, including antigen presentation, cytokine production, T-cell differentiation, T-cell proliferation, T-cell invasion, etc. In this review, we summarize the recent findings regarding the expression or functional changes of GPCRs in MS patients or animal models, and the influences of GPCRs on disease severity upon genetic or phar- macological manipulations.
    [Show full text]
  • Structural Basis of the Activation of the CC Chemokine Receptor 5 by a Chemokine Agonist
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.27.401117; this version posted November 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist One-sentence summary: The structure of CCR5 in complex with the chemokine agonist [6P4]CCL5 and the heterotrimeric Gi protein reveals its activation mechanism Authors: Polina Isaikina1, Ching-Ju Tsai2, Nikolaus Dietz1, Filip Pamula2,3, Anne Grahl1, Kenneth N. Goldie4, Ramon Guixà-González2, Gebhard F.X. Schertler2,3,*, Oliver Hartley5,*, 4 1,* 2,* 1,* Henning Stahlberg , Timm Maier , Xavier Deupi , and Stephan Grzesiek Affiliations: 1 Focal Area Structural Biology and Biophysics, Biozentrum, University of Basel, CH-4056 Basel, Switzerland 2 Paul Scherrer Institute, CH-5232 Villigen PSI, Switzerland 3 Department of Biology, ETH Zurich, CH-8093 Zurich, Switzerland 4 Center for Cellular Imaging and NanoAnalytics, Biozentrum, University of Basel, CH-4058 Basel, Switzerland 5 Department of Pathology and Immunology, Faculty of Medicine, University of Geneva *Address correspondence to: Stephan Grzesiek Focal Area Structural Biology and Biophysics, Biozentrum University of Basel, CH-4056 Basel, Switzerland Phone: ++41 61 267 2100 FAX: ++41 61 267 2109 Email: [email protected] Xavier Deupi Email: [email protected] Timm Maier Email: [email protected] Oliver Hartley Email: [email protected] Gebhard F.X. Schertler Email: [email protected] Keywords: G protein coupled receptor (GPCR); CCR5; chemokines; CCL5/RANTES; CCR5- gp120 interaction; maraviroc; HIV entry; AIDS; membrane protein structure; cryo-EM; GPCR activation.
    [Show full text]
  • Th2 Effector Lymphocytes Regulatory and + Cells Enriched for FOXP3
    CCR8 Expression Identifies CD4 Memory T Cells Enriched for FOXP3 + Regulatory and Th2 Effector Lymphocytes This information is current as Dulce Soler, Tobias R. Chapman, Louis R. Poisson, Lin of September 27, 2021. Wang, Javier Cote-Sierra, Mark Ryan, Alice McDonald, Sunita Badola, Eric Fedyk, Anthony J. Coyle, Martin R. Hodge and Roland Kolbeck J Immunol 2006; 177:6940-6951; ; doi: 10.4049/jimmunol.177.10.6940 Downloaded from http://www.jimmunol.org/content/177/10/6940 References This article cites 68 articles, 27 of which you can access for free at: http://www.jimmunol.org/content/177/10/6940.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology CCR8 Expression Identifies CD4 Memory T Cells Enriched for FOXP3؉ Regulatory and Th2 Effector Lymphocytes Dulce Soler,1 Tobias R.
    [Show full text]
  • Polyclonal Anti-CCR1 Antibody
    FabGennix International, Inc. 9191 Kyser Way Bldg. 4 Suite 402 Frisco, TX 75033 Tel: (214)-387-8105, 1-800-786-1236 Fax: (214)-387-8105 Email: [email protected] Web: www.FabGennix.com Polyclonal Anti-CCR1 antibody Catalog Number: CCR1-112AP General Information Product CCR1 Antibody Affinity Purified Description Chemokine (C-C motif) receptor 1 Antibody Affinity Purified Accession # Uniprot: P32246 GenBank: AAH64991 Verified Applications ELISA, WB Species Cross Reactivity Human Host Rabbit Immunogen Synthetic peptide taken within amino acid region 1-50 on human CCR1 protein. Alternative Nomenclature C C chemokine receptor type 1 antibody, C C CKR 1 antibody, CCR1 antibody, CD191 antibody, CMKBR 1 antibody, CMKR1 antibody, HM145 antibody, LD78 receptor antibody, Macrophage inflammatory protein 1 alpha /Rantes receptor antibody, MIP-1alpha-R antibody, MIP1aR antibody, RANTES receptor antibody, SCYAR1 antibody Physical Properties Quantity 100 µg Volume 200 µl Form Affinity Purified Immunoglobulins Immunoglobulin & Concentration 0.65-0.75 mg/ml IgG in antibody stabilization buffer Storage Store at -20⁰C for long term storage. Recommended Dilutions DOT Blot 1:10,000 ELISA 1:10,000 Western Blot 1:500 Related Products Catalog # FITC-Conjugated CCR1.112-FITC Antigenic Blocking Peptide P-CCR1.112 Western Blot Positive Control PC-CCR1.112 Tel: (214)-387-8105, 1-800-786-1236 Fax: (214)-387-8105 Email: [email protected] Web: www.FabGennix.com Overview: Chemokine receptors represent a subfamily of ~20 GPCRs that were originally identified by their roles in immune cell trafficking. Macrophage inflammatory protein-1 alpha (MIP-1 alpha) and RANTES, members of the beta chemokine family of leukocyte chemo- attractants, bind to a common seven-transmembrane-domain human receptor.
    [Show full text]
  • Use of Alternate Coreceptors on Primary Cells by Two HIV-1 Isolates
    Edinburgh Research Explorer Use of alternate coreceptors on primary cells by two HIV-1 isolates Citation for published version: Cilliers, T, Willey, S, Sullivan, WM, Patience, T, Pugach, P, Coetzer, M, Papathanasopoulos, M, Moore, JP, Trkola, A, Clapham, P & Morris, L 2005, 'Use of alternate coreceptors on primary cells by two HIV-1 isolates', Virology, vol. 339, no. 1, pp. 136-44. https://doi.org/10.1016/j.virol.2005.05.027 Digital Object Identifier (DOI): 10.1016/j.virol.2005.05.027 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Virology Publisher Rights Statement: Copyright 2005 Elsevier Inc. General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 26. Sep. 2021 Virology 339 (2005) 136 – 144 www.elsevier.com/locate/yviro Use of alternate coreceptors on primary cells by two HIV-1 isolates Tonie Cilliersa, Samantha Willeyb, W. Mathew Sullivanb, Trudy Patiencea, Pavel Pugachc, Mia Coetzera, Maria Papathanasopoulosa,1, John P.
    [Show full text]
  • Yabe R Et Al, 2014.Pdf
    International Immunology, Vol. 27, No. 4, pp. 169–181 © The Japanese Society for Immunology. 2014. All rights reserved. doi:10.1093/intimm/dxu098 For permissions, please e-mail: [email protected] Advance Access publication 25 October 2014 CCR8 regulates contact hypersensitivity by restricting cutaneous dendritic cell migration to the draining lymph nodes Rikio Yabe1,2,3,*, Kenji Shimizu1,2,*, Soichiro Shimizu2, Satoe Azechi2, Byung-Il Choi2, Katsuko Sudo2, Sachiko Kubo1,2, Susumu Nakae2, Harumichi Ishigame2, Shigeru Kakuta4 and Yoichiro Iwakura1,2,3,5 1Center for Animal Disease Models, Research Institute for Biomedical Sciences (RIBS), Tokyo University of Science, Noda, Chiba 278-0022, Japan 2Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, University of Tokyo (IMSUT), Minato-ku, Tokyo 108-8639, Japan 3Medical Mycology Research Center, Chiba University, Inohana Chuo-ku, Chiba 260-8673, Japan RTICLE 4 A Department of Biomedical Science, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-ku, FEATURED Tokyo 113-8657, Japan 5Core Research for Evolutional and Technology (CREST), Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012, Japan Correspondence to: Y. Iwakura; E-mail: [email protected] *These authors equally contributed to this work. Received 2 September 2014, accepted 17 October 2014 Abstract Allergic contact dermatitis (ACD) is a typical occupational disease in industrialized countries. Although various cytokines and chemokines are suggested to be involved in the pathogenesis of ACD, the roles of these molecules remain to be elucidated. CC chemokine receptor 8 (CCR8) is one such molecule, of which expression is up-regulated in inflammatory sites of ACD patients.
    [Show full text]
  • 231115072.Pdf
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Dartmouth Digital Commons (Dartmouth College) Dartmouth College Dartmouth Digital Commons Open Dartmouth: Faculty Open Access Articles 8-2003 CCR5 Mediates Specific iM gration of Toxoplasma Gondii—Primed CD8+ Lymphocytes to Inflammatory Intestinal Epithelial Cells Souphalone Luangsay Dartmouth College Lloyd H. Kasper Dartmouth College Nicolas Rachinel Dartmouth College Laurie A. Minns Dartmouth College Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa Part of the Digestive System Diseases Commons, and the Gastroenterology Commons Recommended Citation Luangsay, Souphalone; Kasper, Lloyd H.; Rachinel, Nicolas; and Minns, Laurie A., "CCR5 Mediates Specific iM gration of Toxoplasma Gondii—Primed CD8+ Lymphocytes to Inflammatory Intestinal Epithelial Cells" (2003). Open Dartmouth: Faculty Open Access Articles. 593. https://digitalcommons.dartmouth.edu/facoa/593 This Article is brought to you for free and open access by Dartmouth Digital Commons. It has been accepted for inclusion in Open Dartmouth: Faculty Open Access Articles by an authorized administrator of Dartmouth Digital Commons. For more information, please contact [email protected]. GASTROENTEROLOGY 2003;125:491–500 CCR5 Mediates Specific Migration of Toxoplasma gondii–Primed CD8؉ Lymphocytes to Inflammatory Intestinal Epithelial Cells SOUPHALONE LUANGSAY,* LLOYD H. KASPER,* NICOLAS RACHINEL,* LAURIE A. MINNS,* FRANCK J. D. MENNECHET,* ALAIN
    [Show full text]
  • GM-CSF Modulates the Migratory Phenotype of Vaccine-Induced T Cells by Enhancing CXCR3 Expression
    GM-CSF modulates the migratory phenotype of vaccine-induced T cells by enhancing CXCR3 expression Il-Kang Na Carmen Scheibenbogen Ulrich Keilholz Department of Hematology, Oncology and Transfusion Medicine, Charité Berlin, Campus Benjamin Franklin, Germany. Background Selective chemokine receptor Inflammatory Local tissue microenvironment CXCR3 Tumor tissue CCR4 Skin CCR9 Tissue specific dendritic cells Small intestine Aim of the study Analysis of • Expression of chemokine receptors CXCR3 and CCR4 on vaccine-induced T cells. • Influence of GM-CSF as vaccine adjuvant on chemokine receptor expression. Materials & Methods • Patient samples: stage III/ IV melanoma 1) Tyrosinase peptide + KLH + GM-CSF 2 cohorts 2) Tyrosinase peptide + KLH • T cell response assessment by IFNγ flow cytometry analysis Phase I trial of tyrosinase peptide with adjuvants GM-CSF and KLH 50 50 40 40 30 30 Tyr specific 20 20 PBMC 6 10 10 / 10 0 0 before P13 P14 P15 P15 P16 P17 P17 P18 P18 P19 P11 P11 P12 P12 P13 P31 P32 P33 P34 P35 P35 P36 P36 P37 P38 P38 P39 P40 # 2 # 4 T cells Tyr + KLH Tyr + KLH + GM-CSF # 6 ng i 250 250 200 200 150 150 KLH specific IFNg-secret 100 100 50 50 0 0 P21 P22 P23 P24 P25 P26 P27 P28 P29 P30 P31 P32 P33 P34 P35 P36 P37 P38 P39 Patient identification Scheibenbogen et al. 2003 CXCR3 expression on KLH-specific T cells no antigen KLH 25.2 0.02 24.7 0.06 74.7 0.04 75.1 0.2 Tyr + KLH cohort CXCR3 46.6 0.02 46.0 0.09 52.1 0.01 51.9 0.06 Tyr + KLH + GM-CSF cohort IFNγ CXCR3, CCR4 and CCR9 expression on KLH-specific T cells with GM-CSF without
    [Show full text]
  • CCR6 IL-17 Express the Chemokine Receptor Human T Cells That Are
    Human T Cells That Are Able to Produce IL-17 Express the Chemokine Receptor CCR6 This information is current as Satya P. Singh, Hongwei H. Zhang, John F. Foley, Michael of September 26, 2021. N. Hedrick and Joshua M. Farber J Immunol 2008; 180:214-221; ; doi: 10.4049/jimmunol.180.1.214 http://www.jimmunol.org/content/180/1/214 Downloaded from References This article cites 58 articles, 27 of which you can access for free at: http://www.jimmunol.org/content/180/1/214.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Human T Cells That Are Able to Produce IL-17 Express the Chemokine Receptor CCR61 Satya P. Singh, Hongwei H. Zhang, John F. Foley, Michael N. Hedrick, and Joshua M. Farber2 Some pathways of T cell differentiation are associated with characteristic patterns of chemokine receptor expression.
    [Show full text]
  • Research Article CCR9 Is a Key Regulator of Early Phases of Allergic Airway Inflammation
    Hindawi Publishing Corporation Mediators of Inflammation Volume 2016, Article ID 3635809, 16 pages http://dx.doi.org/10.1155/2016/3635809 Research Article CCR9 Is a Key Regulator of Early Phases of Allergic Airway Inflammation C. López-Pacheco,1,2 G. Soldevila,2 G. Du Pont,1,2 R. Hernández-Pando,3 and E. A. García-Zepeda1,2 1 CBRL, Ciudad de Mexico,´ Mexico 2Departamento de Inmunolog´ıa, Instituto de Investigaciones Biomedicas,´ Universidad Nacional Autonoma´ de Mexico,´ 04510 Ciudad de Mexico,´ Mexico 3Departamento de Patolog´ıa Experimental, Instituto Nacional de Ciencias Medicas´ y Nutricion´ “Salvador Zubiran”,´ Tlalpan, 14080 Ciudad de Mexico,´ Mexico Correspondence should be addressed to E. A. Garc´ıa-Zepeda; [email protected] Received 9 May 2016; Accepted 7 August 2016 Academic Editor: Carolina T. Pineiro˜ Copyright © 2016 C. Lopez-Pacheco´ et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Airway inflammation is the most common hallmark of allergic asthma. Chemokine receptors involved in leukocyte recruitment are closely related to the pathology in asthma. CCR9 has been described as a homeostatic and inflammatory chemokine receptor, but its role and that of its ligand CCL25 during lung inflammation remain unknown. To investigate the role of CCR9 as a modulator of airway inflammation, we established an OVA-induced allergic inflammation model in CCR9-deficient mice. Here, we report the expression of CCR9 and CCL25 as early as 6 hours post-OVA challenge in eosinophils and T-lymphocytes.
    [Show full text]
  • Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?
    cancers Review Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them? Justine Cinier 1,†, Margaux Hubert 1,†, Laurie Besson 1, Anthony Di Roio 1 ,Céline Rodriguez 1, Vincent Lombardi 2, Christophe Caux 1,‡ and Christine Ménétrier-Caux 1,*,‡ 1 University of Lyon, Claude Bernard Lyon 1 University, INSERM U-1052, CNRS 5286 Centre Léon Bérard, Cancer Research Center of Lyon (CRCL), 69008 Lyon, France; [email protected] (J.C.); [email protected] (M.H.); [email protected] (L.B.); [email protected] (A.D.R.); [email protected] (C.R.); [email protected] (C.C.) 2 Institut de Recherche Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France; [email protected] * Correspondence: [email protected] † Co-first authorship. ‡ Co-last authorship. Simple Summary: The immune response against cancer is generated by effector T cells, among them cytotoxic CD8+ T cells that destroy cancer cells and helper CD4+ T cells that mediate and support the immune response. This antitumor function of T cells is tightly regulated by a particular subset of CD4+ T cells, named regulatory T cells (Tregs), through different mechanisms. Even if the complete inhibition of Tregs would be extremely harmful due to their tolerogenic role in impeding autoimmune diseases in the periphery, the targeted blockade of their accumulation at tumor sites or their targeted Citation: Cinier, J.; Hubert, M.; depletion represent a major therapeutic challenge. This review focuses on the mechanisms favoring Besson, L.; Di Roio, A.; Rodriguez, C.; Treg recruitment, expansion and stabilization in the tumor microenvironment and the therapeutic Lombardi, V.; Caux, C.; strategies developed to block these mechanisms.
    [Show full text]